Healthcare provider profile · identity verified

Bertron Brown, M.D.

Internal Medicine · BEAUMONT, TX · NPI 1942289590

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	347	104
Rosuvastatin Calcium	Rosuvastatin Calcium	320	104
Lisinopril	Lisinopril	290	87
Levothyroxine Sodium	Levothyroxine Sodium	272	85
Meloxicam	Meloxicam	248	68
Amlodipine Besylate	Amlodipine Besylate	242	79
Metoprolol Succinate	Metoprolol Succinate	211	68
Simvastatin	Simvastatin	208	65
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	189	59
Pantoprazole Sodium	Pantoprazole Sodium	183	63
Gabapentin	Gabapentin	175	51
Tramadol Hcl	Tramadol Hcl	166	63
Pravastatin Sodium	Pravastatin Sodium	143	45
Allopurinol	Allopurinol	140	39
Losartan Potassium	Losartan Potassium	139	45
Omeprazole	Omeprazole	137	39
Hydrochlorothiazide	Hydrochlorothiazide	125	43
Tamsulosin Hcl	Tamsulosin Hcl	117	39
Clopidogrel	Clopidogrel Bisulfate	102	31
Sertraline Hcl	Sertraline Hcl	97	28
Carvedilol	Carvedilol	89	29
Irbesartan	Irbesartan	86	23
Trazodone Hcl	Trazodone Hcl	83	26
Metformin Hcl	Metformin Hcl	82	28
Paroxetine Hcl	Paroxetine Hcl	81	24
Fluticasone Propionate	Fluticasone Propionate	79	32
Escitalopram Oxalate	Escitalopram Oxalate	78	26
Ozempic	Semaglutide	75	15
Valsartan	Valsartan	71	19
Metoprolol Tartrate	Metoprolol Tartrate	69	25
Furosemide	Furosemide	65	30
Atenolol	Atenolol	64	19
Synthroid	Levothyroxine Sodium	63	21
Famotidine	Famotidine	62	17
Potassium Chloride	Potassium Chloride	62	23
Azithromycin	Azithromycin	61	50
Ezetimibe	Ezetimibe	59	17
Alprazolam	Alprazolam	58	23
Terazosin Hcl	Terazosin Hcl	48	13
Donepezil Hcl	Donepezil Hcl	47	14
Montelukast Sodium	Montelukast Sodium	47	18
Estradiol	Estradiol	45	17
Jardiance	Empagliflozin	45	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	44	20
Nitrofurantoin	Nitrofurantoin Macrocrystal	41	30
Finasteride	Finasteride	39	11
Acetaminophen-Codeine	Acetaminophen With Codeine	38	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	38	15
Albuterol Sulfate Hfa	Albuterol Sulfate	37	18
Farxiga	Dapagliflozin Propanediol	36	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	35	suppressed
Eliquis	Apixaban	34	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	22
Ondansetron Odt	Ondansetron	33	17
Ibandronate Sodium	Ibandronate Sodium	32	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	31	11
Mounjaro	Tirzepatide	30	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	30	15
Citalopram Hbr	Citalopram Hydrobromide	29	suppressed
Enalapril Maleate	Enalapril Maleate	29	suppressed
Glimepiride	Glimepiride	29	11
Cephalexin	Cephalexin	28	18
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Glipizide	Glipizide	27	suppressed
Hydralazine Hcl	Hydralazine Hcl	27	suppressed
Levofloxacin	Levofloxacin	26	19
Ropinirole Hcl	Ropinirole Hcl	26	suppressed
Bupropion Xl	Bupropion Hcl	25	11
Valacyclovir	Valacyclovir Hcl	25	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	21
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Celecoxib	Celecoxib	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Methylprednisolone	Methylprednisolone	23	23
Ventolin Hfa	Albuterol Sulfate	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Nitroglycerin	Nitroglycerin	21	11
Olmesartan Medoxomil	Olmesartan Medoxomil	21	suppressed
Repatha Syringe	Evolocumab	21	suppressed
Amiodarone Hcl	Amiodarone Hcl	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Prednisone	Prednisone	20	12
Warfarin Sodium	Warfarin Sodium	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Lorazepam	Lorazepam	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Tresiba Flextouch U-100	Insulin Degludec	18	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	17	suppressed
Fluconazole	Fluconazole	17	16
Ketoconazole	Ketoconazole	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	13
Propranolol Hcl Er	Propranolol Hcl	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Topiramate	Topiramate	15	suppressed
Trulicity	Dulaglutide	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	13	suppressed
Colesevelam Hcl	Colesevelam Hcl	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Bumetanide	Bumetanide	12	suppressed
Estradiol (Twice Weekly)	Estradiol	12	suppressed
Diazepam	Diazepam	11	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Ramipril	Ramipril	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error